{"id":183421,"date":"2025-10-01T21:01:09","date_gmt":"2025-10-01T21:01:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/183421\/"},"modified":"2025-10-01T21:01:09","modified_gmt":"2025-10-01T21:01:09","slug":"u-s-pfizer-deal-sends-health-stocks-sharply-higher-as-drugmakers-court-trump","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/183421\/","title":{"rendered":"U.S. Pfizer deal sends health stocks sharply higher as drugmakers court Trump"},"content":{"rendered":"<p class=\"c-article-body__text text-pr-5\">European and U.S. healthcare stocks surged on Wednesday, propelled by a deal between Pfizer (<a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/PFE-N\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/PFE-N\/\">PFE-N<\/a>) and President Donald Trump to lower prescription drug prices in the Medicaid program in exchange for tariff relief.<\/p>\n<p class=\"c-article-body__text text-pr-5\">The agreement, seen as less punishing than some within the industry had feared, gives hard-hit global drugmakers a degree of clarity after a volatile year during which Trump has taken aim at the sector over high U.S. medicine prices.<\/p>\n<p class=\"c-article-body__text text-pr-5\">The Pfizer deal is expected to break the seal for other agreements as companies look to hand Trump pricing wins in return for lower tariffs on their drugs to enter the huge U.S. market, investors, company insiders and lobbyists said.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cWe expect EU pharma to follow suit and negotiate with the Trump administration for exemptions,\u201d said Lucy Coutts, investment director at wealth managers JM Finn, which holds shares in GSK, AstraZeneca, Roche and Novo Nordisk.<\/p>\n<p class=\"c-article-body__text text-pr-5\">She said this would likely be in the form of investment in U.S. manufacturing and participation in TrumpRX, a website being launched by Trump for Americans to buy drugs at a discount.<\/p>\n<p class=\"c-article-body__text text-pr-5\">SHOT IN THE ARM FOR PHARMACEUTICAL SHARES<\/p>\n<p class=\"c-article-body__text text-pr-5\">Trump sent letters to 17 leading drug companies in July telling them to slash prices to match those paid overseas. He asked them to respond with binding commitments by September 29. Pfizer is the first drugmaker to announce a deal.<\/p>\n<p class=\"c-article-body__text text-pr-5\">U.S. patients currently pay far more for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.<\/p>\n<p class=\"c-article-body__text text-pr-5\">On Wednesday, Europe\u2019s healthcare sector index cheered the Pfizer deal, closing 5.3% higher, logging its biggest one-day jump since November 2008.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Among the stocks of pharmaceutical companies and their suppliers, Ambu, Sartorius, and Merck , Roche and AstraZeneca rose between 8% and 12% at close. Novo Nordisk and Novartis closed 6.4% and 3.9% higher, respectively.<\/p>\n<p class=\"c-article-body__text text-pr-5\">U.S. pharma stocks also extended the previous session\u2019s gains on Wednesday, lifting the broader healthcare sector up about 2% to an over five-month high. Eli Lilly (<a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/LLY-N\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/LLY-N\/\">LLY-N<\/a>), Pfizer, Merck (<a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/MRK-N\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/MRK-N\/\">MRK-N<\/a>), AbbVie (<a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/ABBV-N\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/ABBV-N\/\">ABBV-N<\/a>) and Bristol Myers Squibb (<a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/BMY-N\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/BMY-N\/\">BMY-N<\/a>) were among the top performers on the benchmark index, with their shares gaining between 3% and 7%.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Shore Capital analyst Sean Conroy said clarity was beginning to emerge on the potential impact of the Trump administration\u2019s \u201cmost-favored-nation\u201d drug pricing proposal and things looked \u201cfar less draconian than feared.\u201d<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cThe announcement yesterday offers some relief to the market,\u201d HSBC analyst Rajesh Kumar said. \u201c(It) may suggest that the deals are now being closed with the U.S. administration offering a path for resolution of the overhang.\u201d<\/p>\n<p class=\"c-article-body__text text-pr-5\">COMPANIES IN \u2018CONSTRUCTIVE\u2019 TALKS WITH US ADMINISTRATION<\/p>\n<p class=\"c-article-body__text text-pr-5\">Britain\u2019s GSK, maker of HIV drugs and vaccines, said it was having constructive conversations with the Trump administration over drug pricing. Germany\u2019s Merck KGaA , which makes cancer drugs, said similar.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Roche said that it and its U.S. unit Genentech remained committed to working with the Trump administration towards strengthening U.S. manufacturing and making medicines more affordable for patients there.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Novo Nordisk, the Danish firm that makes the Wegovy weight-loss injection, said it was in talks with the Trump administration over the \u201cmost-favored-nation\u201d executive order.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Novartis said it remained committed to finding constructive solutions that lower costs for Americans and address price disparities between the U.S. and other high-income countries.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Berenberg analysts estimated that a 50% reduction in Medicaid sales, which account for about 3% of large pharma revenues, would hit sector earnings per share by an average of 4%, with the biggest impact at GSK at around 7% and the smallest at Pfizer at about 1%.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cWe believe that now if the companies are investing in the U.S. they should be on the safe side,\u201d Bernstein analyst Florent Cespedes said, adding that European firms had announced about $200 billion in U.S. investments.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Angelo Meda, head of equities at Banor SIM in Milan, said 2025 was meant to have been a year of expansion for drugmakers, but this had been hit by tariffs. The deal was a relief.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cAny positive news on that front can breathe new life into a sector that is currently trading at relative lows compared to the broader market,\u201d he said.<\/p>\n","protected":false},"excerpt":{"rendered":"European and U.S. healthcare stocks surged on Wednesday, propelled by a deal between Pfizer (PFE-N) and President Donald&hellip;\n","protected":false},"author":2,"featured_media":183422,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[901,888,902,879,877,903,49,48,876,895,896,891,878,875,46,549,295,894,887,914,880,881,893,84,392,889,890,884,904,885,909,910,912,907,911,905,908,882,898,899,714,897,906,865,61,900,892,886,883,913],"class_list":["post-183421","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-alberta","tag-arts-news","tag-bc","tag-breaking-news","tag-breaking-news-video","tag-british-columbia","tag-ca","tag-canada","tag-canada-news","tag-canada-sports","tag-canada-sports-news","tag-canada-trafficcanada-weather","tag-canadian-breaking-news","tag-canadian-news","tag-economy","tag-education","tag-environment","tag-federal-government","tag-foreign-news","tag-globe-and-mail","tag-globe-and-mail-breaking-news","tag-globe-and-mail-canada-news","tag-government","tag-health","tag-healthcare","tag-life-news","tag-lifestyle","tag-local-news","tag-manitoba","tag-national-news","tag-new-brunswick","tag-newfoundland-and-labrador","tag-northwest-territories","tag-nova-scotia","tag-nunavut","tag-ontario","tag-pei","tag-photos","tag-political-news","tag-political-opinion","tag-politics","tag-politics-news","tag-quebec","tag-sports-news","tag-technology","tag-travel","tag-trudeau","tag-us-news","tag-world-news","tag-yukon"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/183421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=183421"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/183421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/183422"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=183421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=183421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=183421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}